Kyverna Therapeutics, Inc. (KYTX)
5.15
-0.01
(-0.19%)
USD |
NASDAQ |
Nov 04, 16:00
5.12
-0.03
(-0.58%)
After-Hours: 20:00
Kyverna Therapeutics Total Liabilities (Quarterly) : 54.27M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 54.27M |
| March 31, 2026 | 61.44M |
| December 31, 2025 | 62.68M |
| September 30, 2025 | 35.21M |
| June 30, 2025 | 42.13M |
| March 31, 2025 | 36.64M |
| December 31, 2024 | 39.93M |
| September 30, 2024 | 36.49M |
| Date | Value |
|---|---|
| June 30, 2024 | 29.61M |
| March 31, 2024 | 28.99M |
| December 31, 2023 | 26.02M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 20.25M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 219.82M |
| Shareholders Equity (Quarterly) | 165.55M |
| Debt to Equity Ratio | 0.1993 |
| Current Ratio | 9.058 |
| Net Debt Paydown Yield | -0.95% |